Overview

The Effects of Erythropoietin (EPO) on the Transfusion Requirements of Very Low Birth Weight Infants

Status:
Completed

Trial end date:
2000-08-01

Target enrollment:

Participant gender:

Summary

This study tested the safety and efficacy of transfusing erythropoietin (Epo) and iron in infants of <1,250g birth weight. For infants 401-1,000g birth weight, we tested whether early erythropoietin (Epo) and iron therapy would decrease the number of transfusions received. For infants 1,001-1,250g birth weight, we tested whether early erythropoietin (Epo) and iron therapy would decrease the percentage of infants who received any transfusions.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

NICHD Neonatal Research Network

Collaborator:

National Center for Research Resources (NCRR)

Treatments:

Epoetin Alfa